Brown Bowel Syndrome: A Rare Complication in Diseases Associated with Long-Standing Malabsorption

Heinz Albrecht\textsuperscript{a} Alexander Hagel\textsuperscript{a} Thomas de Rossi\textsuperscript{a} Tilman T. Rau\textsuperscript{b} Thomas Kirchner\textsuperscript{c} Markus F. Neurath\textsuperscript{a} Martin Raithel\textsuperscript{a}

\textsuperscript{a}Department of Internal Medicine 1 and \textsuperscript{b}Institute of Pathology, University of Erlangen-Nuremberg, Erlangen, and \textsuperscript{c}Department of Pathology, Ludwig Maximilian University Munich, Munich, Germany

Key Words
Brown bowel syndrome · Malabsorption · Lipofuscinosis · Vitamin E

Abstract
Background/Aims: Longtime chronic malabsorption may among other things cause a lack of liposoluble vitamins. Vitamin E deficiency can lead to formation of lipofuscin aggregates. Its deficiency is also associated with an increased lipofuscinosis of the bowel, i.e. brown bowel syndrome.
Methods: Systematic research via Medline on brown bowel syndrome, lipofuscinosis, and vitamin E deficiency was performed. We combined our own clinical experience and a review of the literature for this paper. Its goal is to inform about the possible consequences of severe malabsorption and brown bowel syndrome.
Results: Systematic data about the occurrence of severe malabsorption and brown bowel syndrome are rare. Only about 27 scientific reports can be found on this subject. Brown bowel syndrome is found mostly in conjunction with vitamin E deficiency and lipofuscinosis of the bowel. The clinical findings are caused by both malabsorption and lipofuscinosis. Case reports show a therapeutic effect of vitamin E.
Conclusion: Vitamin deficiency caused by longtime chronic malabsorption can lead to the development of brown bowel syndrome, which is seen as the expression of lipofuscinosis of the bowel, and can cause further clinical disorders. Patients with malabsorption should therefore be monitored regarding their vitamin E levels.

Introduction

Chronic long-term or severe malabsorption can be the cause of a recurring or persisting deficiency in proteins, lipids, electrolytes, vitamins, and other trace elements. In particular, a deficit in fat-soluble vitamins such as vitamin A, D, E, and K is associated with symptoms of dry skin, concentration disorders, fatigue, poor wound healing, coagulatory disorders, increased susceptibility to infection, and other cognitive and neurological deficits [1]. The main function of vitamin E (tocopherol) as an antioxidant membrane lipid is to guard against auto-oxidation or pathological oxidation induced by free radicals; thus, a deficiency in this vitamin causes damage to the phospholipid layer of the mitochondrial membrane via free radicals with the resulting development of lipofuscin deposits [2]. Such a deficiency is also associated with an increase in
in lipofuscinosis of the bowel, i.e. brown bowel syndrome [3, 4].

The aim of this study is to familiarize the reader more closely with the symptoms and complications of brown bowel syndrome as the result of an underlying malabsorption disorder. We present the results of a literature search and our own clinical experience.

**Definition of Brown Bowel Syndrome**

Brown bowel syndrome was first reported in the literature in 1963 and signifies lipofuscinosis mainly in the small bowel that is characterized macroscopically by an orange-brown appearance [5] (fig. 1). In addition to the atrophic villi that can be viewed microscopically as a sign of an underlying malabsorptive disorder, a brown coloring particularly of the apical enterocytes demonstrates the increased lipofuscin deposits (fig. 2).

These lipofuscin aggregates are found inside the cell, mainly in the smooth muscle cells of the muscular coat, but also in the muscular layer of the mucosa [6–9]. Whereas more lipofuscin accumulates in the heart, liver tissue, and adrenal glands with aging, the mechanism underlying its development has not yet been determined. It is thought to be a degradation product of degenerating mitochondria, and in advanced brown bowel syndrome it has also been detected – though rarely – in other organs, such as the thyroid or intestinal lymph nodes [3, 8, 10, 11].

Other authors have suggested that autophagocytotic processes may represent a model for the formation of lipofuscin [6–8].

**Presumed Pathogenesis and Clinical Symptoms**

The cause of this particular form of lipofuscinosis, one that is associated with brown coloration in the small bowel, has not been elucidated yet. It is generally thought to be due to chronic vitamin E deficiency, which is the result of deficient enteral uptake of fat-soluble tocopherol in malabsorption syndromes such as celiac disease [12–14].

Deficiencies of a range of nutrients, including vitamin E, are a common complication following malabsorptive forms of obesity surgery. Indeed, brown bowel syndrome was recently reported in a patient in whom a jejunoileal bypass had been created 26 years previously [2]. So even a ‘jejunoileal bypass’ as an unusual old procedure may be associated with brown bowel syndrome [2]. Over the course of time the vitamin E deficiency or lipofuscinosis may cause neuronal functional disorders that, as a result, affect bowel motility to a considerable degree [15].

Advanced brown bowel syndrome presents several symptoms in addition to the signs of the underlying malabsorption disorder. This includes general dystrophia, weight loss, protein deficiency edema, motility problems (e.g. vomiting, flatulence, and pseudo-obstructions), liver cirrhosis, signs of vitamin deficiency involving severe os-
Brown Bowel Syndrome

According to current data, it is difficult in general to determine whether the disease underlying the brown bowel syndrome is responsible for the increased risk of carcinoma in patients with celiac disease and chronic pancreatitis. In other words, it is not known whether the chronic inflammation alone contributes to neoplastic progression or whether the vitamin E deficiency resulting from chronic malabsorption is responsible for this [23].

### Other Diseases Associated with Brown Bowel Syndrome

Table 1 presents several diseases in which the development of brown bowel syndrome has been reported.

In some studies, a pronounced vitamin E deficiency has been discovered, which could help explain the association with brown bowel syndrome. To date, however, a prospective observation of decreased vitamin E levels to development of the brown bowel syndrome has not yet been established in humans. Following malabsorptive techniques of obesity surgery (in particular biliopancreatic diversion), vitamin E deficiency is common. Screening and appropriate supplementation (not only of vitamin E deficiency, but also of a wide range of other macro- and micronutrients) are therefore a crucial aspect of routine long-term follow-up [2].

Brown bowel syndrome has mainly been found to be associated with malabsorptive disorders of the small bowel, such as celiac disease and intestinal lymphoma [4, 23, 24]. Furthermore, an association between congenital bowel malformations such as small intestinal atresia has also been established [26].

Lipofuscin aggregates have also been discovered in the smooth muscle cells of the muscular layer of the mucosa in patients with chronic inflammatory bowel diseases such as Crohn’s disease and severe cases of ulcerative enteritis [7, 27]. In one case report, brown bowel syndrome developed in a patient with known Crohn’s disease within 5 years [27]. Here, the typical lipofuscin deposits were found in the cytoplasm and in the perinuclear regions of the smooth muscle cells, which gave rise to the notion that brown bowel syndrome might possibly be a ‘mitochondrial myopathy’. The loss of mitochondrial function and resulting disorder in energy production ultimately causes atrophy and atonia of the smooth muscle [3, 4]. In fact, the damage to the smooth muscle of the bowel present in existing brown bowel syndrome can explain many functional symptoms or pathophysiological findings, including bowel atonia, intussusception, intes-

#### Table 1. Summary of diseases associated with or predisposing to the development of brown bowel syndrome

<table>
<thead>
<tr>
<th>Keynotes</th>
<th>Example</th>
<th>Reference</th>
</tr>
</thead>
<tbody>
<tr>
<td>Malabsorption</td>
<td>celiac disease</td>
<td>[14, 28]</td>
</tr>
<tr>
<td>Maldigestion</td>
<td>chronic pancreatitis</td>
<td>[23]</td>
</tr>
<tr>
<td></td>
<td>liver disease, cholestasis</td>
<td>[11]</td>
</tr>
<tr>
<td>Chronic inflammation</td>
<td>Crohn’s disease</td>
<td>[27]</td>
</tr>
<tr>
<td></td>
<td>ulcerative enteritis</td>
<td>[25]</td>
</tr>
<tr>
<td>Motility disturbances</td>
<td>intestinal pseudo-obstruction</td>
<td>[4]</td>
</tr>
<tr>
<td></td>
<td>bowel atonia</td>
<td>[7]</td>
</tr>
<tr>
<td></td>
<td>anorectal functional disturbances</td>
<td>[29]</td>
</tr>
<tr>
<td></td>
<td>intestinal atresia</td>
<td>[26]</td>
</tr>
<tr>
<td>Association with malignancy</td>
<td>gastrointestinal adenocarcinoma</td>
<td>[18]</td>
</tr>
<tr>
<td></td>
<td>lymphoma</td>
<td>[24]</td>
</tr>
<tr>
<td>Postoperative conditions</td>
<td>obesity surgery</td>
<td>[2]</td>
</tr>
<tr>
<td></td>
<td>jejunoileal bypass</td>
<td></td>
</tr>
<tr>
<td>Vitamin E deficiency</td>
<td>α-β-lipoproteinemia</td>
<td>[30]</td>
</tr>
</tbody>
</table>

Complications such as electrolytic shift, protein and nutrient deficiency with resulting cachexia, and increased susceptibility to infection can develop from severe malabsorption. They can also be the result of morphological changes in the affected bowel segment such as bowel atonia, intussusception, and intestinal pseudo-obstruction or gastrointestinal bleeding [4, 7, 17–20]. Such complications can be fatal.

### Association with Malignant Diseases

The concomitant presentation of brown bowel syndrome and carcinoma in the small intestine has only been reported in one isolated case so far [18]. However, brown bowel syndrome has been reported to arise concomitantly with other gastrointestinal adenocarcinomas more frequently, but precise data are still lacking because of its rarity [21–23].
tinal pseudo-obstruction, various anorectal functional disturbances, etc. [4, 7, 17].

Exocrine pancreas insufficiency can cause inadequate resorption of fat-soluble vitamins (vitamins A, D, E, and K) [31, 32]. Chronic vitamin E deficiency can then induce brown bowel syndrome [12, 13].

Likewise, severe malabsorption syndrome and celiac disease are also both associated with chronic vitamin E deficiency, which in turn produces the lipofuscin aggregates typical for brown bowel syndrome and the macroscopically apparent brown coloration of the small bowel. Indeed, a case report was published concerning a patient in whom radiologically visible changes were detected that were similar to those observed in intestinal lymphoma [24]. Histologically, brown bowel syndrome was confirmed in this patient by a transmural biopsy taken from a segment of the small bowel in which a brown coloration had been observed. The authors postulate that the lipofuscin deposits in the muscular layer of the mucosa caused the changes that could be detected radiologically and which are similar to the radiological changes observed for intestinal lymphoma [24].

Micronutrient metabolism deficiency can also be caused by various other malabsorption syndromes. Here, the liver should be mentioned in particular, as it is the organ primarily responsible for metabolism. Via biliary secretion, the liver regulates fat digestion and the absorption of fat-soluble vitamins. In the literature, case reports can be found of patients with liver cirrhosis and resulting malabsorption and brown bowel syndrome [11]. However, no studies have been performed in which serum vitamin E levels were correlated with the extent of nutritional deficiency and the development of brown bowel syndrome.

One case study reported massive bleeding in the lower gastrointestinal tract in conjunction with the presence of brown bowel syndrome [20]. The authors postulated that the functional loss of the mitochondria in the smooth muscle cells, which is typical for this disease, contributed to or caused the bleeding. Histologically, lipofuscin deposits were demonstrated in the smooth muscle cells of the arterial and venous walls, which ultimately caused hemorrhagia and persistent bleeding [20].

**Diagnosis and Treatment**

Among many other serological parameters (e.g. C-reactive protein, albumin, total protein, transglutaminase IgA, etc.), serum levels of fat-soluble vitamins and carotenoids are determined for the diagnosis of malabsorptive disorders. In addition, the fat content in stool samples can be measured to gain further information. Imaging procedures (abdominal ultrasound, MRI, barium enema, and CT) and endoscopic examinations including multiple biopsies from the small bowel should also be performed.

The term vitamin E constitutes a collective name for all natural and synthetic tocol and tocotrienol derivatives, which qualitatively demonstrate the biological activity of α-tocopherol [33, 34]. Tocopherol is the umbrella term for all mono-, di-, and trimethyl tocotrienols. To determine the levels of the individual tocopherols, high-performance liquid chromatography, gas chromatography, and the combined techniques high-performance liquid chromatography-mass spectrometry and gas chromatography-mass spectrometry are employed [33, 34]. Further studies in this area would be desirable to more precisely distinguish the actual vitamin E deficiency in the various conditions by measuring serum levels in patients with malabsorptive disorders (celiac disease, chronic pancreatitis, and chronic inflammatory bowel diseases), motility disorders (recurrent pseudo-obstruction, myopathy), and in patients with chronic atresia or atonia and after bariatric surgery [2, 7].

In this context, we still need to clarify what role quantitative serum vitamin E levels play (cutoff values for the development of brown bowel syndrome). For the pathological diagnosis based on small bowel biopsy, it is important to know that lipofuscin often cannot be detected with certainty by using conventional hematoxylin-eosin staining. Therefore, if brown bowel syndrome is suspected, e.g. in conjunction with recurring motility disorders of thus far unexplained etiology or when a brown-golden coloration of the small bowel is apparent endoscopically or macroscopically (differential diagnosis Whipple disease), the pathologist should be informed accordingly about these particular findings. Further specialized histological examinations can then be performed to confirm or exclude the presence of this disease. Here, supplementary UV light microscopy is mainly applied or electron microscopy is used for evaluation [9, 35].

Several authors have reported for confirmed brown bowel syndrome that long-term vitamin supplementation improved the malabsorption syndrome and was accompanied by regression of the lipofuscin deposits [26]. The required daily dose of vitamin E for brown bowel syndrome depends on the serum levels of vitamin, clinical symptoms, and supply of polyunsaturated fatty acids. Generally, the dose of vitamin E for therapeutic substitution lies between 250 and 1,000 IU of vitamin E (corre-
sponding to 150–600 mg per day). For comparison, the dose of vitamin E for prophylactic supplementation for adults is 20–35 mg per day.

**Conclusion**

Diseases involving chronic severe malabsorption are rare; however, they can develop in individual cases of refractory small bowel disease, advanced chronic pancreatitis, or liver diseases, result from a lack of vitamin E, or also develop as a complication of malabsorptive bariatric surgery. These conditions are also associated with the risk of brown bowel syndrome, which in turn induces further disease symptoms, recurring motility disorders, and diarrhea. Therefore, for the treatment of malabsorption syndromes and diseases of the liver and pancreas, the development of brown bowel syndrome associated with the aforementioned symptoms should be considered for differential diagnosis in order to initiate treatment with vitamin E supplementation and/or other fat-soluble vitamins in a timely manner.

**References**


Brown Bowel Syndrome

Digestion 2014;89:105–109
DOI: 10.1159/000357228

109